Associated Papers
Discovery and preclinical evaluations of drug candidate DA-0157 capable of overcoming EGFR drug-resistant mutation C797S and EGFR/ALK co-mutations.
He P et al.
European Journal of Medicinal Chemistry, 2025
Image-Based Phenotypic Profiling Enables Rapid and Accurate Assessment of EGFR-Activating Mutations in Tissues from Lung Cancer Patients.
Lei Q et al.
Journal of the American Chemical Society, 2025
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S8
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.
Ali A et al.
Embo Molecular Medicine, 2018
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Kobayashi Y et al.
Molecular Cancer Therapeutics, 2017
Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase.
Truong TH et al.
Cell Chemical Biology, 2016
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
25699077 (PubMed )
Supplement: Table1.PDF
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Godin-Heymann N et al.
Molecular Cancer Therapeutics, 2008
Select a paper to view details